Status:

COMPLETED

A Repeatability and Reproducibility Study of the EarliPoint™ Device

Lead Sponsor:

EarliTec Diagnostics, Inc

Conditions:

Autism Spectrum Disorder (ASD)

Eligibility:

All Genders

16-30 years

Brief Summary

The study is a prospective randomized repeatability and reproducibility (R\&R) study of the EarliPoint DeviceTM in pediatric subjects 16-30 months of age. The study will enroll subjects who are both c...

Detailed Description

Subjects will undergo testing with the same two (2) devices, with one (1) testing session per device per subject, with each testing session yielding three (3) measurements per endpoint per subject, fo...

Eligibility Criteria

Inclusion

  • Children between 16 and 30 months of age.
  • No acute illnesses by physical observation.
  • Normal or corrected-to-normal vision, and normal or corrected-to-normal hearing.
  • Communicate meaningfully with patent in English, and the principal investigator /the study team.
  • Parent or legal guardian is able to read and understand the Informed Consent Form.
  • Parent voluntarily provides written informed consent.

Exclusion

  • Genetic disorders (e.g., Fragile X, Williams Syndrome, Tuberous Sclerosis, muscular Dystrophy, Neurofibromatosis, Down Syndrome).
  • History or presence of a clinically significant medical disease or a mental state that might confound the study result as assessed by the investigator, such as severe hearing or visual impairment; or uncontrolled epilepsy or seizure disorder, et al.
  • Acute exacerbations of chronic illnesses likely to prevent successful data collection.
  • Receiving therapies that may affect vision.
  • Therapies that may affect the ability to focus.
  • Known allergies or sensitivity to the plastic, leather, or metal components.
  • Unable or unwilling to sit in a child safety seat.
  • Use of any investigational drug, therapies or diagnostic device within the past 14 days.

Key Trial Info

Start Date :

May 7 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 17 2021

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT04860986

Start Date

May 7 2021

End Date

November 17 2021

Last Update

November 8 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Emory University

Atlanta, Georgia, United States, 30329